Figure S3A presents the tumour size distribution of each group, and no significant differences were found between groups (p > 0.05). In E3D group, anti-PD-1 was administered from day 6 p.i. (500 μg/dose) followed by repeated injections (250 μg/dose) every 3 days. In the IMS group, anti-PD-1 was administered from day 6 p.i. (500 μg/dose) followed by repeated injections (250 μg/dose) with IMS (every 6 days). The experimental schedule for each group is shown in Figure S3B. Here, PDCD1 is linked to neoplasm.